← 返回

CAR-T 细胞:概念、应用、局限性与拟议解决方案概述

英文原题:Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.

查看英文原题

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.

PubMed 2022/06/22(内容时间) Front Bioeng Biotechnol Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

由B细胞和T细胞协调的适应性免疫在保护机体免受病原体侵袭方面发挥关键作用。通过基因工程改造这些免疫细胞,也可以增强机体抵御癌症的能力。人们已发现多种癌症治疗策略,并评估其治疗自身免疫性疾病和感染性疾病的效果。其中最先进的技术之一是嵌合抗原受体(CAR)T细胞疗法,这是一种肿瘤学领域的开创性疗法。成功的临床试验促使美国食品药品监督管理局批准了6种CAR-T 产品,用于治疗血液系统恶性肿瘤。然而,CAR-T 疗法要成为癌症的一线防御手段仍有多种障碍。临床前研究和临床试验已评估多种创新CAR-T 设计,显示出很大发展潜力。正在开展的CAR用于实体瘤和HIV治疗适用性研究也呈现良好前景。此外,研究人员提出了克服该疗法局限的新方案。本综述概述这项新兴技术的现有知识,包括CAR-T 结构、不同应用、局限及拟议的解决方案。

展开英文摘要原文

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the body from pathogenic invaders and can be used as tools to enhance the body's defense mechanisms against cancer by genetically engineering these immune cells. Several strategies have been identified for cancer treatment and evaluated for their efficacy against other diseases such as autoimmune and infectious diseases.

One of the most advanced technologies is chimeric antigen receptor (CAR) T-cell therapy, a pioneering therapy in the oncology field. Successful clinical trials have resulted in the approval of six CAR-T cell products by the Food and Drug Administration for the treatment of hematological malignancies.

However, there have been various obstacles that limit the use of CAR T-cell therapy as the first line of defense mechanism against cancer. Various innovative CAR-T cell therapeutic designs have been evaluated in preclinical and clinical trial settings and have demonstrated much potential for development. Such trials testing the suitability of CARs against solid tumors and HIV are showing promising results.

In addition, new solutions have been proposed to overcome the limitations of this therapy. This review provides an overview of the current knowledge regarding this novel technology, including CAR T-cell structure, different applications, limitations, and proposed solutions.

论文信息

作者
Alnefaie A、Albogami S、Asiri Y、Ahmad T、Alotaibi SS、Al-Sanea MM、Althobaiti H
第一作者单位
Department of Medical Services, King Faisal Medical Complex, Taif, Saudi Arabia.Saudi Arabia
通讯作者单位
Chief of Medical Department, King Faisal Medical Complex (KFMC), Taif, Saudi Arabia.Saudi Arabia
文献类型
综述
期刊
Frontiers in bioengineering and biotechnology2022
原文标识
PubMed 35814023 · DOI 10.3389/fbioe.2022.797440